Amgen funds development of intracellular drugs

By Flora Southey contact

- Last updated on GMT

iStock/darnellvfx
iStock/darnellvfx

Related tags: Protein

Amgen has teamed with Feldan Therapeutics and Elasmogen in an exclusive research agreement to develop and deliver intracellular biologics.

Canada-based Feldan’s Shuttle platform and Scotland-based Elasmogen’s soloMER technology will be employed in the Amgen-funded collaboration.

The Feldan Shuttle technology is a peptide-based delivery method that facilitates the introduction of foreign proteins into cells.

Elasmogen’s soloMERs are small, robust binding domains which, according to Elasmogen, make them resistant to changes in pH in intracellular conditions. 

“Our soloMERs are the smallest naturally occurring binding domains in the animal kingdom and they are incredibly stable, making them the perfect candidates for surviving the conditions inside the cell,” ​Elasmogen CEO Caroline Barelle told BioPharma-Reporter.com.

Intracellular biologics

Currently, all approved biologic antibody therapeutics act on extracellular targets.

According to Feldan CEO François-Thomas Michaud, intracellular delivery enables access to an increased number of targets.

To date, intracellular targeting for therapeutic intervention has largely been reliant on small molecules, because large biologics cannot enter the cells.

“Intracellular delivery and binding of biologics can bridge the gap between small molecules and biologics,”​ Feldan said.

“By combining our technology with Feldan’s shuttle, we have achieved not only localisation inside the cell, but inside the nucleus, as well as opening up a whole new world of possible therapeutic targets,” ​Barelle told us.

Exclusive agreement

The research agreement is funded by Amgen, and is exclusive to the development and delivery of two, undisclosed targets.

Feldan and Elasmogen established a partnership in 2016 for the development of intracellular biologics.

Barelle told us the companies are speaking to a number of other potential partners, but did not reveal details. 

Related topics: Bio Developments, Cell lines

Related news

Show more

Related products

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

Related suppliers

Follow us

Products

View more

Webinars